Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Multi-Lineage Dysplasia Assessment By Immunophenotype in Myeloproliferative Neoplasms (MPN): Correlation with Disease' Variant, Clinical Features and Molecular Genetics

Francesco Mannelli, MD, Sara Bencini, Benedetta Peruzzi, Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, PhD, Francesca Gesullo, BSci, Blerina Jance, Marida Bonetti, Roberto Caporale, Francesco Annunziato, PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 1668.

https://doi.org/10.1182/blood-2019-125843

Published: 2019

Journal Articles

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Paola Guglielmelli, MD PhD, Niccolò Bartalucci, PhDBSc, Elisa Contini, PhD, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Simone Romagnoli, BSc, Lara Mannelli, MD, Francesco Mannelli, MD, Giacomo Coltro, MD, Alessandro Pancrazzi, PhD, Valentina Ariu, BSci, Sara Fiaccabrino, Roberto Semeraro, Alberto Magi, PhD, Carmela Mannarelli, PhD, Francesca Gesullo, BSci, Chiara Paoli, PhD, Alessandro M. Vannucchi, MD

Blood (2019) 134 (Supplement_1): 2968.

https://doi.org/10.1182/blood-2019-129094

Published: 2019

Journal Articles

Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV)

Ayalew Tefferi, MD, Paola Guglielmelli, MD PhD, Terra L. Lasho, PhD, Giacomo Coltro, MD, Christy Finke, BS, Giuseppe Gaetano Loscocco, MD, Mythri Mudireddy, MBBS, Benedetta Sordi, MD, Natasha Szuber, MD, Giada Rotunno, PhD, Rangit Vallapureddy, MBBS, Annalisa Pacilli, PhD, Maura Nicolosi, MD, Domenico Penna, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Alessandro M. Vannucchi, MD

Blood (2018) 132 (Supplement 1): 578.

https://doi.org/10.1182/blood-2018-99-109715

Published: 2018

Journal Articles

Comparative Genomic and Expression Analysis of Chronic and Blast-Phase Cells in Patients with Myeloproliferative Neoplasms

Paola Guglielmelli, MD PhD, Tiziana Fanelli, BiSc, Valentina Ariu, BSci, Giada Rotunno, PhD, Annalisa Pacilli, PhD, Elisa Contini, PhD, Alberto Magi, PhD, Roberto Semeraro, Simona Salati, PhD, Alberto Bosi, MD, Francesco Mannelli, MD, Rossella Manfredini, PhD, Alessandro M. Vannucchi, MD

Blood (2018) 132 (Supplement 1): 1777.

https://doi.org/10.1182/blood-2018-99-112894

Published: 2018

Journal Articles

Next-Generation Sequencing (NGS) in Childhood Myeloproliferative Diseases (MPD)

Michelina Santopietro, MD, Giovanna Palumbo, MD, Maria Luisa Moleti, MD, Anna Maria Testi, MD, Luisa Cardarelli, MD, Nicola Monaco, MDcal Student, Francesco Malaspina, MD, Camilla Presicce, MDcal Student, Sonia Maria Orlando, Alessandro Pancrazzi, PhD, Annalisa Pacilli, PhD, Giada Rotunno, PhD, Alessandro M. Vannucchi, MD, Robin Foà, MD, Fiorina Giona, MD

Blood (2018) 132 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2018-99-118102

Published: 2018

Journal Articles

Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study

Paola Guglielmelli, MD PhD, Naseema Gangat, MBBS, Giacomo Coltro, MD, Terra L. Lasho, PhD, Giuseppe Gaetano Loscocco, MD, Christy Finke, BS, Benedetta Sordi, MD, Mythri Mudireddy, MBBS, Giada Rotunno, PhD, Natasha Szuber, MD, Annalisa Pacilli, PhD, Rangit Reddy Vallapureddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Alessandro M. Vannucchi, MD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3040.

https://doi.org/10.1182/blood-2018-99-110045

Published: 2018

Journal Articles

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

Alessandro M. Vannucchi, Annalisa Pacilli, PhD, Giada Rotunno, MSc, PhD, Francesco Mannelli, Chiara Paoli, BiSci, Carmela Mannarelli, MSc, PhD, Annalisa Franci, RN, Tiziana Fanelli, BiSc, Alessandro Pancrazzi, PhD, Francesca Gesullo, MSc, Giuditta Corbizi Fattori, BiSc, Alberto Bosi, MD, Paola Guglielmelli, MD PhD

Blood (2017) 130 (Supplement 1): 4195.

https://doi.org/10.1182/blood.V130.Suppl_1.4195.4195

Published: 2017

Journal Articles

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

Alessandro M. Vannucchi, Paola Guglielmelli, MD PhD, Terra L. Lasho, PhD, Giada Rotunno, MSc, PhD, Carmela Mannarelli, MSc, PhD, Annalisa Pacilli, PhD, Animesh Pardanani, MBBS PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Curtis A. Hanson, MD, Francesco Mannelli, Rhett P. Ketterling, MD, Naseema Gangat, MBBS, Alessandro Rambaldi, MD Prof, Francesco Passamonti, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Ayalew Tefferi, MD

Blood (2017) 130 (Supplement 1): 200.

https://doi.org/10.1182/blood.V130.Suppl_1.200.200

Published: 2017

Journal Articles

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Blood (2017) 130 (Supplement 1): 1657.

https://doi.org/10.1182/blood.V130.Suppl_1.1657.1657

Published: 2017

Journal Articles

Beyond JAK-STAT: Contribution of Abi-1, STAT3, and NF-κB Signaling to Pathogenesis of Myeloproliferative Neoplasms

Anna Dorota Chorzalska, PhD, John Morgan, PhD, Diana Olguta Treaba, MD, Adam J Olszewski, MD, Kara Lombardo, Roberta Zini, BSc, PhD, Annalisa Pacilli, PhD, Alexander Tepper, John L. Reagan, MD, Leszek Kotula, MD, Peter J. Quesenberry, MD, Philip Gruppuso, MD, Rossella Manfredini, BSc, PhD, Alessandro M. Vannucchi, Patrycja Dubielecka, PhD

Blood (2017) 130 (Supplement 1): 4210.

https://doi.org/10.1182/blood.V130.Suppl_1.4210.4210

Published: 2017

Journal Articles

Bone Marrow-Specific Loss of ABI1 Induces Myelofibrosis through a Mechanism Involving Activation of NFκB

Blood (2016) 128 (22): 1203.

https://doi.org/10.1182/blood.V128.22.1203.1203

Published: 2016

Journal Articles

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Paola Guglielmelli, PhDMD, Giada Rotunno, MSc, PhD, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Daniela Pietra, PhD, Silvia Salmoiraghi, BSc, Carmela Mannarelli, MSc, PhD, Francesco Passamonti, MD, Alessandro Rambaldi, MD, Giovanni Barosi, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 943.

https://doi.org/10.1182/blood.V128.22.943.943

Published: 2016

Journal Articles

Prognotic Impact of Mutations in Systemic Mastocytosis

Lisa Pieri, MD PhD, Giada Rotunno, MSc, PhD, Francesca Gesullo, MSc, Tiziana Fanelli, MSc, Giuditta Corbizi Fattori, MSc, Annalisa Pacilli, PhD, Federica Scarfì, MD, Maria Loredana Iorno, MD, Fabio Almerigogna, MD, Roberto Salerno, MD, Paola Guglielmelli, MD PhD, Roberta Zanotti, MD, Alessandro M. Vannucchi, MD

Blood (2016) 128 (22): 1953.

https://doi.org/10.1182/blood.V128.22.1953.1953

Published: 2016

Journal Articles

Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Alessandro Pancrazzi, BS, Tiziana Fanelli, MSc, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Chiara Paoli, BS, Lucia Merli, BSN, Marker Mahtab, Ana Rodriguez, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4087.

https://doi.org/10.1182/blood.V126.23.4087.4087

Published: 2015

Journal Articles

Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes

Giada Rotunno, MSc, Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Tiziana Fanelli, MSc, Carmela Mannarelli, MSc, Alessandro Pancrazzi, BS, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4091.

https://doi.org/10.1182/blood.V126.23.4091.4091

Published: 2015

Journal Articles

A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis

Paola Guglielmelli, MD PhD, Giada Rotunno, MSc, Tiziana Fanelli, MSc, Annalisa Pacilli, PhD, Laura Calabresi, BiSci, Alessandro Pancrazzi, BS, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1627.

https://doi.org/10.1182/blood.V126.23.1627.1627

Published: 2015

Journal Articles

JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment

Annalisa Pacilli, PhD, Paola Guglielmelli, MD PhD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Rajmonda Fjerza, MD, Alessandro M. Vannucchi

Blood (2015) 126 (23): 1630.

https://doi.org/10.1182/blood.V126.23.1630.1630

Published: 2015

Journal Articles

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

Paola Guglielmelli, MD PhD, Giada Rotunno, Annalisa Pacilli, PhD, Elisa Rumi, MD, Vittorio Rosti, MD, Federica Delaini, MD, Margherita Maffioli, MD, Tiziana Fanelli, MSc, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Raimonda Fjerza, MD, Daniela Pietra, PhD, Daniela Cilloni, MD, Francesco Passamonti, Alessandro Rambaldi, MD, Giovanni Barosi, MD, Tiziano Barbui, MD, Mario Cazzola, MD, Alessandro M. Vannucchi, MD

Blood (2015) 126 (23): 351.

https://doi.org/10.1182/blood.V126.23.351.351

Published: 2015

Journal Articles

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

Paola Guglielmelli, MD PhD, Annalisa Pacilli, PhD, Giada Rotunno, MSc, Francesca Gesullo, BS, Alessandro Pancrazzi, BS, Lisa Pieri, MD PhD, Emanuela Sant'Antonio, MD, Carmela Mannarelli, MSc, Giuseppe Loscocco, Chiara Paoli, BS, Lucia Merli, BSN, Alessandro M. Vannucchi

Blood (2015) 126 (23): 353.

https://doi.org/10.1182/blood.V126.23.353.353

Published: 2015

Journal Articles

JAK2 V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib

Lisa Pieri, MDPhD, Alessandro Pancrazzi, MSc, Annalisa Pacilli, PhD, Claudia Rabuzzi, BSci, Giada Rotunno, MSc, Paola Guglielmelli, MD PhD, Rajmonda Fjerza, MD, Chiara Paoli, MSc, Tiziana Fanelli, MSc, Alberto Bosi, MD, Srdan Verstovsek, MD PhD, Alessandro Maria Vannucchi, MD

Blood (2014) 124 (21): 3185.

https://doi.org/10.1182/blood.V124.21.3185.3185

Published: 2014

NARROW

Multi-Lineage Dysplasia Assessment By Immunophenotype in Myeloproliferative Neoplasms (MPN): Correlation with Disease' Variant, Clinical Features and Molecular Genetics

Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs)

Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV)

Comparative Genomic and Expression Analysis of Chronic and Blast-Phase Cells in Patients with Myeloproliferative Neoplasms

Next-Generation Sequencing (NGS) in Childhood Myeloproliferative Diseases (MPD)

Mutations and Thrombosis in Essential Thrombocythemia and Polycythemia Vera: Mayo-Careggi Alliance Study

Changing Patterns, and Clinical Correlates, of Mutations in Patients with Myelofibrosis over Treatment with Ruxolitinib or Hydroxyurea

MIPSS70: Mutation-Enhanced Prognostic System for Transplant Age Patients with Primary Myelofibrosis

A Distinct Mutation Profile Might Contribute to the Dismal Outcome of Triple Negative Patients with Primary Myelofibrosis

Beyond JAK-STAT: Contribution of Abi-1, STAT3, and NF-κB Signaling to Pathogenesis of Myeloproliferative Neoplasms

Bone Marrow-Specific Loss of ABI1 Induces Myelofibrosis through a Mechanism Involving Activation of NFκB

Differences in Clinical and Molecular Characteristics and Outcome in Prefibrotic and Overt Primary Myelofibrosis According to 2016 WHO Criteria. a Study on 639 Patients of the Agimm Group

Prognotic Impact of Mutations in Systemic Mastocytosis

Mutational Profile of Patients with Polycythemia Vera Treated with Ruxolitinib in the Phase III Controlled Response Study

Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes

A Greater Mutational Complexity May Contribute to the Differential Prognostic Impact of Type 1/Type 1-like Versus Type 2/Type2-like Calreticulin Mutations in Primary Myelofibrosis

JAK2V617F Clonal Architecture in MPNs during JAK2 Inhibitor Treatment

Prognostic Impact of Bone Marrow Fibrosis in Primary Myelofibrosis: A Study of Agimm Group on 540 Patients

Impact of Underlying Mutational Profile, and Changes during Treatment, in MPN Patients Treated with JAK Inhibitors

JAK2 V617F Complete Molecular Remission in Long-Term Follow-up of Patients with Polycythemia Vera and Essential Thrombocythemia Treated with Ruxolitinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only